Feb 15 2011

Early Oncology Partnering Forum

San Francisco

Image by Louis Grenier via stock.xchng

From 21-22 February 2011, Cato Research will be attending the Early Oncology Partnering Forum held in San Francisco, CA.  This conference facilitates and encourages discussion and collaborations between companies that are developing innovative products with more established companies as partners.

The conference will begin with a Partnering Perspective Presentation.  Representatives from Amgen, Eli Lilly, and QIAGEN will speak during this session and will address some of the criteria that they look for when considering partnership with early stage companies.  The remainder of the conference is designed to showcase the early stage companies and is organized into sessions for diagnostics and biomarkers, technology/tools, small molecules, and large molecules products.

Lynda Sutton, COO of Cato Research and President of Cancer Advances, and Daniel Pharand, CFO of Cato Research and Cancer Advances, will be presenting data from Cancer Advances’ clinical trials in pancreatic cancer.  Their presentation is titled, “Personalized Oncology Product Development: Immune Response to Gastrin-17 Maximizes Clinical Benefit in Cancer Patients,” and will be featured during the Large Molecules session of Day 2.

Cancer Advances is a biotechnology company focused on impacting the progression of gastrointestinal cancers by enhancing the adaptive immune system to inhibit the hormone gastrin. The lead compound, Polyclonal Antibody Stimulator (PAS) is designed to elicit antibodies against human gastrin-17 and has been tested in multiple clinical trials including trials in gastric, pancreatic, and colorectal cancer.  Overall, across all indications, patients who generate an antibody response to PAS show improved survival over those that do not develop a response to PAS.